ID   TCO-1 [Human thyroid carcinoma]
AC   CVCL_M839
SY   TCO-I
DR   ArrayExpress; E-MTAB-783
DR   BioSample; SAMN03471663
DR   cancercelllines; CVCL_M839
DR   CGH-DB; 59-1
DR   Cosmic; 909763
DR   Cosmic; 2054090
DR   FANTOM5_SSTAR; 10783-110G9
DR   GEO; GSM827182
DR   IARC_TP53; 27018
DR   JCRB; FDSC0019
DR   JCRB; JCRB0239
DR   Progenetix; CVCL_M839
DR   Wikidata; Q54971891
RX   PubMed=1516062;
RX   PubMed=2181436;
RX   PubMed=3986962;
RX   PubMed=9177455;
RX   PubMed=9290701;
RX   PubMed=16924234;
RX   PubMed=20215515;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Doubling time: ~26 hours (Note=Lot 11032003) (JCRB=JCRB0239).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:7773; NF2; Simple; p.Tyr101Ter (c.303T>A); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: JCRB; FDSC0019; true.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): JCRB=JCRB0239; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 9,13
ST   D18S51: 17
ST   D21S11: 29,32.2
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 18
ST   TH01: 6,7
ST   TPOX: 12
ST   vWA: 17,19
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-04-25; Version: 29
//
RX   PubMed=1516062;
RA   Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.;
RT   "Role of p53 mutations in endocrine tumorigenesis: mutation detection
RT   by polymerase chain reaction-single strand conformation
RT   polymorphism.";
RL   Cancer Res. 52:5061-5064(1992).
//
RX   PubMed=2181436; DOI=10.1073/pnas.87.7.2409; PMCID=PMC53698;
RA   Higashi T., Sasai H., Suzuki F., Miyoshi J., Ohuchi T., Takai S.-i.,
RA   Mori T., Kakunaga T.;
RT   "Hamster cell line suitable for transfection assay of transforming
RT   genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2409-2413(1990).
//
RX   PubMed=3986962; DOI=10.1093/carcin/6.4.549;
RA   Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T.,
RA   Kondo S.;
RT   "Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA
RT   damage in tumor cell strains from Japanese patients and demonstration
RT   of MNNG hypersensitivity of Mer xenografts in athymic nude mice.";
RL   Carcinogenesis 6:549-553(1985).
//
RX   PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3;
RA   Satake S., Sugawara I., Watanabe M., Takami H.;
RT   "Lack of a point mutation of human DNA topoisomerase II in
RT   multidrug-resistant anaplastic thyroid carcinoma cell lines.";
RL   Cancer Lett. 116:33-39(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//